Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
TPIV-110 by Marker Therapeutics for Ductal Carcinoma In Situ: Likelihood of Approval
TPIV-110 is under clinical development by Marker Therapeutics and currently in Phase I for Ductal Carcinoma In Situ. According to...